Mavacamten

The American College of Cardiology Scientific Session was held April 2 to 4 in Washington, D.C. For the first time since 2019, the meeting was held inperson, and Healio Cardiology Today w onsite to cover the latest in cardiology.

Healio and Cardiology Today have compiled a list of the most-read news in cardiology of April 2022.

The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first cardiac myosin inhibitor to be permitted for use in the United States, Bristol Myers Squibb announced.

Mavacamten (Bristol Myers Squibb) vs. placebo in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

WASHINGTON — The cardiac myosin inhibitor mavacamten, compared with placebo, reduced the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy, according to results of the VALOR-HCM trial.

The 2022 American College of Cardiology Scientific Session will be held live in Washington, D.C., from April 2 to 4, and virtually, with 39 late-breaking trials and featured clinical research presentations.

Artificial intelligence to assess changes in ECGs may represent a novel method to evaluate disease status and treatment response to mavacamten in patients with obstructive hypertrophic cardiomyopathy, researchers reported.

The virtual 2022 American College of Cardiology Scientific Session will be held from April 2 to 4, and will feature 25 late-breaking clinical trials, 10 featured clinical research presentations and numerous abstract presentations.